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New Melanoma
Staging System
Reflects Key
Prognostic
Factors
by Kerry L. Wright

ince its establishment
in 1959, the American
Joint Committee on
Cancer (AJCC)
has recognized the
"dynamic" nature of cancer staging
and has organized regular reviews
of standard staging systems. Most
recently, the staging criteria for 13
common cancer disease sites have
come under review in preparation
for publication of the sixth edition
of the AJCC Cancer Staging
Manual.
(Continued on next page)
Dr. Bonnie Kemp and Dr. Victor Prieto,

associate professors in the Department of
Pathology , examine a melanoma biopsy specimen
in the laboratory. Advances in pathologic and
surgical techniques contributed to the develop~
ment of a new melanoma staging system.
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New Melanoma Staging System
( Continued from page 1)

The first group to make recommen,
dations to the AJCC was the 18,member
Melanoma Staging Committee. For the
first time, the committee's recommenda,
tions were data,driven-developed after
compilation and analysis of complete
prognostic factor data from more than
17,000 patients with melanoma from
13 international centers-rather than
derived only from a review of the
literature. The results of this analysis,
as well as advances in surgical and
pathologic techniques, led to the
development of a new melanoma
staging system, which was recently
approved by the executive committee
of the AJ CC and by the International
Union Against Cancer. The revised
criteria, which include changes to the
T (primary tumor), N (regional lymph
node), and M (distant metastasis)
portions of the TNM classification as
well as to the stage groupings, will be
implemented worldwide and used by

more than 5,000 tumor registries in
the United States when the new A]CC
Cancer Staging Manual is published
in 2002.
"There are dramatic changes in the
staging system that will better reflect
prognosis and more accurately represent
the nature of the disease," said Jeffrey
E. Gershenwald, M.D., an assistant
professor in the Department of Surgical
Oncology at The University of Texas
M. D. Anderson Cancer Center and
a member of the Melanoma Staging
Committee. M. D. Anderson Professor
of Surgical Oncology Merrick I. Ross,
M.D., is also a member.
Owing to the histologic nature of
several newly incorporated prognostic
factors, pathologic analysis will play a
larger role than ever in the new system,
said Victor G. Prieto, M.D., an associate
professor in the Department of Pathol,
ogy. Cox multivariate regression analysis
of the data identified several prognostic

Disease-Site Task Forces to
Recommend Staging Revisions
The American Joint Committee on Cancer (AJCC) has organized the
following 13 disease,site task forces to make recommendations for revised
TNM staging criteria for the sixth edition of the A]CC Cancer Staging
Manual:

Bone
Breast
Central Nervous System
Colorectal
Digestive System
Genitourinary
Gynecologic

Head and Neck
Lung and Esophagus
Lymphomas
Melanoma
Ophthalmic
Soft Tissue Sarcoma

Each multidisciplinary task force consists of at least e ight members who
are governed by new policies and procedures that require them not only to
review relevant literature before making their recommendations but also to
prepare new data and to perform their own meta,analyses when ufficient
data are available. The Melanoma Task Force is the first to have its recom,
mendations approved by the executive committee of the AJCC and the
International Union Against Cancer.
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factors that were being used in clinical
trials but h ad not been reflected in the
previous staging system, including
ulceration of the primary tumor, number
of lymph nodes with metastases, site
of distant metastases, and elevation in
levels of serum lactate dehydrogenase
(LDH) .
"Because of these features, pathology
will definitely be key in staging," said
Dr. Prieto. "Most of the staging crite,
ria-I would say in more than 90% of
tumors-will be based upon the pathol,
ogy report," he said.
For the T classification, tumor
thickness (Breslow thickness) is now
considered a more important prognostic
variable than level of invasion (Clark
level). The current breakpoints for
Breslow th ickness and for subdividing
the T classific, tion-0.75 mm, 1.5 mm,
and 4 mm- will be replaced with
whole,integer breakpoints of 1 mm,
2 mm, and 4 rnm, which are as reliable
as the old one~ and more clinically
convenient, ~:Jld Dr. Gershenwald.
The new syste n also inaugurates the
use of ulceration as a prominent staging
criterion. For a given T subclass, the
presence of ulceration will place the
disease in the next highest subclass.
With respect to the N classification,
most studies showed that the number
of lymph nodes with disease present was
more prognostically significant than
the size of the largest metastasis, said
Dr. Gershenwald.
"So now, rather than the size of the
lymph node metastasis, the number of
lymph nodes will be the stratification
scheme," he said. Moreover, the data
showed that ulceration, traditionally
a prognostic factor for primary tumors,
was an independent adverse factor even
among patients with node,positive
disease. Therefore, the presence of
ulceration will place the disease in
the next N subclass. The nodes will be
classified according to whether they
have micro, or macrometastases, as
patients with clinically occult me,
tastases fared better than those with
clinically evident disease.
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"We are still
dealing with
patients, and we
try to get the best
diagnosis and the
best treatment
possible for a
particular
patient. That is
our goal."
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- Victor G. Prieto, M.D.,
associate professor,
Department of Pathology

Faculty and staff listen to a presentation during a weekly multidisciplinary melanoma conference at
M. D . Anderson. Here, attendees from many departments discuss clinical and pathologic information
to develop workup and treatment recommendations for patients with complex cases of melanoma.
Further analysis showed that patients
with metastases to the skin, subcutaneous tissue, or distant lymph nodes had
better prognoses than those with
metastases to other sites. The staging
committee concluded that the site of
metastasis was more predictive of
outcome and more reliable than the
number of metastases. Thus, under the
new criteria, a patient's M classification
will be determined by location of
metastases.
"In addition, for the first time in
melanoma staging, a serum factor will
be incorporated," said Dr. Gershenwald,
"because the presence of an abnormally
high lactate dehydrogenase level in
patients with distant metastatic disease
seems to portend the worst prognosis."
In the new system, patients with distant
metastases and elevated serum LDH
levels will be assigned to the highest
M subclass, regardless of where the
metastases are located.
Information from the separate
TNM classifications is also combined
to identify stage groupings, traditionally

defined as stages I to IV. Since pathologic staging is more precise than
clinical staging, in the revised system,
patients will be assigned stage
subgroupings based on ulceration,
number of metastatic nodes, and type
of metastases, as determined by
microstaging and available data from
lymphadenectomy or sentinel lymph
node biopsy.
Sentinel node biopsies are now
routinely performed on patients with
tumors at least 1 mm thick, so most
patients will have some type of pathologic information available, said Dr.
Gershenwald. According to Dr. Prieto,
biopsy specimens will continue to be
evaluated by staining with hematoxylin
and eosin, followed by immunohistochemical analysis, which recently has
been shown to be more sensitive than
traditional histology. Several members
of the Department of Surgical Oncology,
including Dr. Ross, Dr. Gershenwald,
Associate Professor Paul E Mansfield,
M.D., and Associate Professor Jeffrey E.
Lee, M.D., are currently involved in the

multi-institutional Sunbelt Melanoma
Trial to compare the sensitivity of
standard histologic examination with
that of the polymerase chain reaction
(PCR ).
"Using PCR, we may be able to
identify very early spread of melanoma
to lymph nodes," said Dr. Lee, adding
that the technique could be able to
detect a single melanoma cell in a pool
of up to one million normal cells. Dr.
Ross is the institutional study chairman
of the Sunbelt trial, in which patients
with a sentinel lymph n ode that is
negative for melanoma by microscopic
evaluation but positive for the possible
presence of melanoma by PCR are
randomized to receive one of three
possible treatments: observation, lymph
node dissection, or lymph node dissection plus interferon alfa-2b for one
month.
"Only by doing these studies will we
be able to determine if extra treatments
are beneficial for patients with very
early spread of melanoma," Dr. Lee said.
(Continued on page 4)
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New Melanoma
Staging System
(Continued from page 3)

When standard histological and
immunohistochemical analyses are used,
the actual time spent making or con,
firming a diagnosis of melanoma varies
depending on the complexity of a
particular case. Pathologists can spend
anywhere from 15 seconds to several
hours examining a single slide, and a
diagnosis can be made from just one
slide-prepared from a standard punch
biopsy, for example-or up to 200 slides
for larger tumors and more difficult
cases, said Dr. Prieto. However, knowing
the clinical information for a specific
case can also be of tremendous help in
making a diagnosis.
"According to the old school, it had
to be a blinded diagnosis, so you would
give the diagnosis with whatever mate,
rial you had. But today, most of the time
pathologists insist on having the clinical
information," Dr. Prieto said. For
example, he continued, if an elderly
person comes to the clinic with a
pigmented lesion on the face and the
biopsy results do not provide a distinc,
tion between melanoma and sun damage,
then just knowing the size of the lesion
can help in the differential diagnosis.
For more complex cases, however, it
is important for physicians from many
disciplines to meet and discuss all
available clinical and pathologic
information. At M. D. Anderson,
surgeons, pathologists, oncologists,
radiation therapists, nurses, and
physician's assistants meet once a week
at a multidisciplinary planning confer,
ence, during which selected patients are
examined and workup and treatment
recommendations are made.
So, although the new melanoma
staging system will rely heavily on
pathologic data, "We are still dealing
with patients," said Dr. Prieto, "and
we try to get the best diagnosis and the
best treatment possible for a particular
patient. That is our goal." •
FOR MORE INFORMATION, contact Dr.
Gershenwald at (713) 792,6936, Dr.
Prieto at (713) 792,3187, or Dr. Lee
at (713) 792,7218 .
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Updated M. D. Anderson Web
to Meet the Online Needs of P
by Dawn Chalaire

through a staff directory and the online
Research Report and Guide for Referring

efore launching its
redesigned Web site
in September 2000,
The University of
Texas M. D. Anderson Cancer
Center conducted extensive
marketing research, gleaning
insights from patient focus groups
and interviews with referring
physicians, faculty members,
and the public. What the re . .
searchers discovered was that
patients and physicians often
want very different things from
a medical center Internet site.

Physicians.

B

According to Alan Powell, director
of Internet Services, patients usually
arrived at the M. D. Anderson Web site
looking for information about their
specific diagnosis and trying to make
a decision about whether to seek
treatment at M. D. Anderson. Physi,
cians, on the other hand, wanted to
know how the Web site could facilitate
and support the referral process.
"For example," Powell said, "they
wanted to know if the new Web site
could do a better job of helping them
find a doctor to talk to about their
patient."
The physicians interviewed were
also interested in viewing educational
programs, using the Internet and e,mail
in the referral process, and finding
clinical trials for their patients.
The Web site's new home page
accommodates these divergent interests
by immediately directing users to one of
three categories-"Patients and Public,"
"Cancer Professionals," and "About
M. D. Anderson." The home page for
cancer professionals contains clinical
and educational resources and informa,
tion about M. D. Anderson faculty

Information about clinical trials
at M. D. Anderson can be accessed
through both the "Cancer Professionals"
and "Patients and Public" home pages.
In the coming year, a search engine will
be added to the clinical trials site.
The site also makes it easier than
ever for physicians to refer their patients
to M. D. A nderson, with a revised
online referral form that is simple to
use. Since an online referral form was
introduced with the original Web site
in December 1997, about 2,000 patients
have been referred to M. D. Anderson
via the Internet.
"That's been very effective, and it
continues to grow," Powell said. "We've
seen a very dramatic increase in the
number of patients referring themselves.
We've seen a much steadier increase in
the number of physicians and physician
offices using the Web site."
Physicians who explore the Web
site will discover a new physician
relations page ( www.mdanderson.org/
PhysicianRelations) that provides
referring physicians with easy, compre,
hensive access to the M. D. Anderson
programs and services that are designed
to support physicians in the community.
Mitchell Morris, M.D., senior vice
president and chief information officer
at M. D. Anderson,• said that one of
the most important new features of
the redesigned site is a content manage,
ment tool that allows many different
departments within the institution
to simultaneously create content for
the site.
"That is going to give us the paten,
tial to add many more kinds of features
and functions over the coming months
and years," Dr. Morris said.
In the future, physicians will be able
to earn continuin g medical education
(CME) credits online through Net
Grand Rounds, a program that replays a
videotape from M . D. Anderson Grand

Site Designed
hysicians and Patients

w. Keith Hoots, M.D.
habeenNmed
the February 2001
Educ:ator of1he Mor!th
for his commitment to
the educatron of
pedletrlclenslnthe
pracdce of hematology.

Wednesday, 2n 112001

M. D. Anderson has
amassed a wealth of
resources on cancer research,
prevention, education and
patient care, and much of this
information is available to other
cancer professionals. Check
out our extensive research
library and publications list, or
sign up for educational
programs and seminars.
Looking for a colleague or
department at M. D. Anderson?
You can find them here. This
site also can help you refer
patients to us.

Today"s Headline

New and improved M. O.
Mderson library opens in Clark
Clinic • It was hard to miss the
construction signs in the R. lee
Clari< Clinic lobby as wori<ers
prepared space for M. D.
Aiderson's new and improved
Patient/Family Library, which
opened Feb. 13... .m:&!:!1
Other News

From the "Cancer
Professionals" home
page on the updated
M. D. Anderson
Web site, physicians
can find links to
clinical and scientific
resources, informa
tion about patient
referral, professional
education, and lists
of faculty and staff.

Featured Sites

Cancer

Professionals

NIH Regional Seminar Spring 2001

Cancer-Related Fatigue 2001
Conference
Survey for Cancer S1Jrvivors

Done

Rounds presentations and includes a
transcript of the presentation, slides,
and links to related information.
"Very often, doctors don't have the
time to go to a meeting but can take 10
minutes to come online and view some
of this content, take a test, and get some
CME credit," Dr. Morris said.
A similar approach to patient
education is in the works. Soon,
patients will be able to view patient
education content about cancer preven
tion and detection, cancer treatment,
managing side effects, and supportive
care issues.
Also under development is a highly
secure Web site for M. D. Anderson
patients. Called "mymdanderson.org,"
the site will allow patients to access
information using a password and
identification code that will be given
to them upon admission. (The informa
tion on the Web site will be encrypted,
and the software used will meet all

"We've always felt
that the more
patients know about
their treatment and
their disease, the
better they do with
their treatment
program."
- Mitchell Morris, M.D.,
senior vice president
and chief information officer*

federal and state regulations governing
patient privacy.) Patients will be able
to use the site to refill prescriptions,
check their schedule and request
changes, view their billing and insur
ance information, and make payments

online. They will also be able to
request customized patient education
materials to be delivered to their
home.
"We've always felt that the more
patients know about their treatment
and their disease, the better they do
with their treatment program," Dr.
Morris said.
Dr. Morris stressed that redesigning
and adding content to the Internet site
is an ongoing, collaborative project.
"It really is a team effort. So many
people have put their time into this and
their expertise and their talent. It's been
fun to watch it grow," he said. •
The M. D. Anderson Internet site address
is www.mdanderson.org.
'Effective January 31, 2001, Dr. Morris resigned as
senior vice president and CIO to become vice president
far the First Consulting Group. As a consultant with
M. D. Anderson, he will continue to contribute to the
development of mymdanderson.arg.
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Educational Conferences Explore
Issues Related to Cancer Care and Research

T

h e Office of Continuing
Medical Education and
C onference Services at The
University of Texas M. D.
Anderson Cancer Center will be
sponsoring several educational confer,
ences from late March through early
October 2001. Topics include fatigue,
cancer biology, mechanisms of cell
death and disease, and leukemia in
adolescen ts and young adults.
Many conferences offer continuing
education credit, including American

Medical Association/Physicians Recog,
nition Award (AMA /PRA) Category 1
and other professional certification
(approved according to the criteria
of the Accreditation Council for
Continuing Medical Education).
For additional information and
updates about these conference , a
well as other conference and in, h u
educational events at M. D. Ander on,
see the Continuing Medical Informa,
tion and Conference Service Web it
at www.mdanderson.org/~meeting r

Professional Conferences Sponsored by The University of Texas M. D. Anderson Cancer Centeli
Date

•• Conference
(Location)

March 23-24

Management of Cancer Treatment-Induced
Diarrhea and Carcinoid Syndrome (New
Orleans)

it

Chairpersons
(Contact)
Jaffer A. Ajani, M.D.
(Veronica Moreno,

it

Continuing Education
Credit (Credit Hours)

@
-

AMA/PAA Category 1 (4

713-792-442 1)

,_

March 24-25

2nd Annual Cancer-Related Fatigue Conference (Houston)

Charles S. Cleeland, Ph. D.

AMA/PAA Category 1 (1 2

April 24-25

Japan/U.S. Cancer Therapy Symposium
(JUCTS) New Concepts in the Biology and
Treatment of Cancer (La Jolla, CA)

Ritsuko Komaki, M. D.

AMA/PAA Category 1 (1'

April 28

Houston Society of Clinical Pathologists 41 st
Annual Conference "Tumors of the Kidney,
Urinary Bladder, and Testis: Recent Advances
in Diagnosis and Classification" (Houston)

Jae Y. Ro, M.D., Ph. D.

AMA/PAA Category 1 (6 ..,

May 5-6

6th Annual Hands-On & High-Tech Workshop
for the Difficult Airway (Houston)

Joseph S. Chiang, M. D.
(Mary Ann Schneider,
713-792-691 1)

AMA/PAA Category 1 (1L.

May 16-18

Conferencia Internacional de HematoOncologfa Medica (Houston)

Sergio Giralt, M.D., and
Jorge E. Cortes, M.D.

June 1-2

6th Human Dimensions Conference (Houston)

Eduardo Bruera, M. D.

June 2-5

2nd Mechanisms of Cell Death and Disease:
Advances inTherapeutic Intervention
(Falmouth , MA)

Timothy J. McDonnell, M.D.,
Ph.D.

AMA/PAA Category 1 (1 8. 5)

September 7-8

AVA 2001: Issues in Adolescent and Young
Adult Leukemias (Houston)

Sima Jeha, M.D. , and Hagop
M. Kantarjian, M.D.

AMA/PAA Category 1 (12.0)

September 20-22

Ovarian Cancer Conference (Houston)

David M. Gershenson, M. D.

AMA/PAA Category 1 (16.0)

September 30October 2

23rd Annual Pharmacy Symposium (Houston)

Sharon Bronson, M.S., and
William Dana, Pharm. D.

October 2-5

54th AnnualSymposium on Fundamental
Cancer Research: Mechanisms for Cell
Growth & Differentiation (Houston)

Richard Behringer, Ph. D.,
and Sharon Roth, Ph. D.
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AMA/PRA Category 1 (15.5)
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,... Preventing Cancer: Food for Thought

W

e've all heard about the importance of a healthy diet,
but did you know that the foods you eat-or don't
eat-can affec t your risk of cancer? According to the
American Cancer Society (ACS) , approximately one third of the
500,000 cancer deaths in the United States each year are linked
to diet and nutrition. But changing the way you eat now and
incorporating more healthy foods into your diet can actually
help reduce your risk of cancer.

Certain nutrients such as vitamins
can protect DNA from damage and can
prevent or delay the development of
cancer, even in people with increased
genetic risk. A low,fat, plan t,based
diet-including ample servings of
vegetables, fruits, whole grains, and
beans-seems to offer the best protec,
tion against many kinds of cancer,
including those of the esophagus, oral
cavity, stomach, colon, rectum, and
lungs.
Eating five or more servings of fruits
and vegetables every day is the "single
most important dietary factor for
lowering risk of cancer," according to
the ACS. Unfortunately, this is not the
way many Americans eat. Surveys show
that most people eat an average of only
two to three servings of fruits and
vegetables per day and consume too
many high,calorie, high,fat foods.
Researchers from the National Cancer
Institute determined that only 1% of
American children meet all the na,
tional dietary recommendations for
daily servings of grains, vegetables,
fruits, meat, and dairy foods, and 16%
meet none of the recommendations.
Improving your diet may seem
daunting, but it doesn't have to be.
A series of small changes-substituting
a low,fat food for a high,fat one and
including fruits and vegetables in your
meals, for example-can reap big
rewards. Here are some dietary guide,
lines, along with suggestions to help
you put them into practice.

■ Eat five to
nine servings
of fruit and
vegetables
each day.
(A serving is a
1/2 cup of cooked fruit or vegetable or
one medium,sized raw fruit or veg,
etable.) It's not as hard as you think. Try
to include one or two servings with
every meal or snack. Have fruit avail,
able for healthy snacks and precut
vegetables in the refrigerator ready to
eat with a nonfat dip. Add some extra
grated or chopped vegetables to your
casseroles.

■ Eat six to 11

o\e·gr~0

F ,r ~

servings ~f
whole-gram
...,
t9)[
o
foods each day.
~~) ~
(A serving is one
....,.. 2
slice of bread, 1/2
cup cooked pasta or rice, or one ounce
of cereal.) Look for foods that list whole
grain as their first ingredient. These are
rich in dietary fiber, which may reduce
your risk of colorectal cancer.

i

■

Eat a low-fat
diet. High,fat
diets are associated
with cancers of
the breast, colon,
and prostate.
Switch to low,fat ( 1% fat or less) or
nonfat dairy products. Remove fat from
all meat and skin from chicken before
cooking, or substitute beans for meat
in your meals.

■ Limit alcohol
consumption.
If you drink at all,
don't have more
than two drinks
per day (no more
than one drink per day for women) .
Drinking is linked to breast, colon,
and liver cancers and, when combined
with smoking, greatly increases the risk
of lung cancer and head and neck
cancers.
■ Remember,
calories do
count. Obesity
is defined as
being 20% or
more above your
ideal weight. Being obese can increase
your risk of certain types of cancer
( including breast and colon cancer) as
well as cause a myriad of other health
problems including diabetes, high blood
pressure, stroke, and coronary heart
disease.

Changing your eating habits
at any age can improve your
health and reduce your cancer
risk. Start embracing these
recommendations today, and
share them with those you
care about. •

For more information , contact
your physician or contact the
M. D. Anderson Information Line:

(f)

(800) 392-1611 within
the United States, or

(f)

(713) 792-6161 in Houston
and outside the United States.

January 2001
©2001 The University of Texas
M. D. Anderson Cancer Center

n pr fit Org.
U .. P tag
PAID
. 7052

OncoLog
Department of Scientific Publications-234
M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, Texas 77030
www 3.mdanderson.org/-oncolog

Address Service Requested

DiaLog

OncoL

Leukeinia: Setting the "Stage"
for Effective Treatments

The University of Texas
M. D. Anderson Cancer Center
President

J hn M nd I hn, M.D.

Emil J Freireich, M.D.
Professor, Department of Leukemia
The correct staging
of a malignant
disease is a powerful
tool for estimating
prognosis, which has
a major impact on
the choice of
treatment. Most
staging systems
discriminate between
local, regional, and
systemic disease, but leukemia almost
always presents as a systemic illness.
Therefore, the staging systems developed
for leukemia have been used as models for
developing staging systems for systemic
disease in other malignancies.
As with every malignancy, histopathologic morphology is a major prognostic
factor for leukemia. The separation between
poorly differentiated (acute) and welldifferentiated (chronic) forms of leukemia
was appreciated at the tum of the century.
Next, it was noted that leukemia could
emerge from myeloid, or bone marrowderived, cells or from lymphoid-derived cells.
With the introduction of combination
chemotherapy in the 1960s, the first cures
of a systemic, syngeneic tumor--childhood
acute lymphoblastic leukemia-were
described. This therapy identified a new
prognostic factor, the age of the patient. The
older the patient, the more poorly the
disease responded to treatment and the less
likely a curative outcome would be achieved.
The major breakthrough in the staging
8 / OncoLog

of systemic illnesses was the de cription in
1960 of the Philadelphia chromo ome.
This discovery revealed that hematological
remissions did not change the cytogenetic
pattern in the marrow. Treatment with
interferon, however, made it po ible to
achieve cytogenetic remi ion in patien
with chronic myeloid leukemia (CML) , and
this was demonstrated to be a ociated with
a significant increase in urvival. Thu , th
major prognostic factor for raging CML
became the percentage of bone marrow
metaphases in which the Philad lphia
chromo ome was pre ent.
With the opening of the cytogen tic
era, nonrandom chromo ome abn rmaliti
were identified in the acute myel id
leukemias, and these abnormalitie b cam
the most important progno tic factor.
Another important advance wa the
description of monoclonal antib die ,
which identified antigen on the urface of
leukemic cells that were unique to leuke,
mias. New molecular biological technique
that characterize cytogenetic abnormalitie
at the molecular level have proven ex,
tremely useful in identifying patient who
are likely to have their di ease eradicated in
contrast to those who have re idual di ea e
and require additional treatment.
Clearly, now and in the future, the
staging of systemic disea e will increasingly
rely on the molecular characterization of
the genetic abnormality as ociated with
that malignancy and its phenotypic con e,
quence, and the objective mea urement of
degree of residual di ea e will be the mo t
important way to identify treatments that
prolong survival or bring about a cure.
©2001 T~ UniuernryofTuas
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